Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients

References

• AzizKMEffect of fasting Ramadan in diabetes control status – application of extensive diabetes education, serum creatinine with HbA1c statistical ANOVA and regression models to prevent hypoglycemiaRecent Pat EndocrMetab Immune Drug Discov201373233 251
   Google Scholar
• SaltiIBénardEDetournayBEpidiar Study GroupA population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) studyDiabetes Care2004272306 231115451892
   PubMed Web of Science ®Google Scholar
• AmielSDixonTMannRJamesonKHypoglycaemia in type 2 diabetesDiabet Med200825245 25418215172
   PubMed Web of Science ®Google Scholar
• Alvarez GuisasolaFTofe´ PovedanoSKrishnarajahGHypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) studyDiabetes Obes Metab200810Suppl 125 3218435671
   PubMed Web of Science ®Google Scholar
• ZammittNFrierBHypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalitiesDiabetes Care2005282948 296116306561
   PubMed Web of Science ®Google Scholar
• YarahmadiSLarijaniBBastanhaghMetabolic and clinical effects of Ramadan fasting in patients with type II diabetesJ Coll Physicians Surg Pak200313329 33212814530
   PubMedGoogle Scholar
• KhatibFShafagojYMetabolic alterations as a result of Ramadan fasting in noninsulin-dependent diabetes mellitus patients in relation to food intakeSaudi Med J2004251858 186315711655
   PubMed Web of Science ®Google Scholar
• MygindAKristiansenMWittrupINorgaardLSPatient perspectives on type 2 diabetes and medicine use during Ramadan among Pakistanis in DenmarkInt J Clin Pharm201335281 28823354808
   PubMed Web of Science ®Google Scholar
• LarijaniBZahediFSanjariMThe effect of Ramadan fasting on fasting serum glucose in healthy adultsMed J Malaysia200358678 68015190653
   PubMedGoogle Scholar
• AhmadaniMYRiazMFawwadAHydrieMZHakeemRBasitAGlycaemic trend during Ramadan in fasting diabetic subjects: a study from PakistanPak J Biol Sci200811162044 204719266915
   PubMedGoogle Scholar
• Al SifriSBasiounnyAEchtayARamadan Study GroupThe incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomized trialInt J Clin Pract201165111132 114021951832
   PubMed Web of Science ®Google Scholar
• AravindSRAl TayebKIsmailSBRamadan Study GroupHypoglycaemia in sulphonylurea treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country country observational studyCurr Med Res Opin2011271237 124221506631
   PubMed Web of Science ®Google Scholar
• AravindSRIsmailSBBalamuruganRHypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic studyCurr Med Res Opin20122881289 129622738801
   PubMed Web of Science ®Google Scholar
• CesurMCorapciogluDGursoyAA comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fastingDiabetes Res Clin Pract200775141 14716815586
   PubMed Web of Science ®Google Scholar
• SariRBalciMKAkbasSHAvciBThe effects of diet, sulfonylurea, and repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during RamadanEndocr Res200430169 17715473127
   PubMed Web of Science ®Google Scholar
• BakinerOErtorerMEBozkirliETutuncuNBDemiragNGRepaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in RamadanActa Diabetol200946163 6518825302
   PubMed Web of Science ®Google Scholar
• BurdenMCulturally sensitive care: managing diabetes during RamadanBr J Community Nurs2001611581 58511832802
   PubMedGoogle Scholar
• LokeSCRahimKFKanesvaranRWongTWA prospective cohort study on the effect of various risk factors on hypoglycaemia in diabetics who fast during RamadanMed J Malaysia20106513 621265238
   PubMedGoogle Scholar
• SalehiMAulingerBAD’ AlessioDATargeting beta-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretinsEndocr Rev200829367 37918292465
   PubMed Web of Science ®Google Scholar
• WangQBrubakerPLGlucagon like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db miceDiabetologia2002451263 127312242459
   PubMed Web of Science ®Google Scholar
• TrumperATrumperKTrusheimHArnoldRGokeBHorschDGlucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signalingMol Endocrinol2001151559 157011518806
   PubMed Web of Science ®Google Scholar
• KrarupTImmunoreactive gastric inhibitory polypeptideEndocr Rev19889122 1343286232
   PubMed Web of Science ®Google Scholar
• AhrénBFoleyJThe islet enhancer vildagliptin: mechanisms of improved glucose metabolismInt J Clin Pract200862Suppl 1598 1418173812
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMAThe incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet20063681696 170517098089
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO)Diabetes Mellitus: Report of a Study Group Technical Report Series 727Geneva, SwitzerlandWHO1985
   Google Scholar
• Expert Committee on the Diagnosis and Classification of Diabetes MellitusReport of the expert committee on the diagnosis and classification of diabetes mellitusDiabetes Care1997201183 11979203460
   PubMed Web of Science ®Google Scholar
• MitrakouAKelleyDMokanMRole of reduced suppression of glucose production and diminished early insulin release in impaired glucose toleranceN Engl J Med199232622 291727062
   PubMed Web of Science ®Google Scholar
• DunningBEGerichJEThe role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implicationsEndocr Rev200728253 28317409288
   PubMed Web of Science ®Google Scholar
• LarssonHBerglundGAhrenBGlucose modulation of insulin and glucagon secretion is altered in impaired glucose toleranceJ Clin Endocrinol Metab1995801778 17827775622
   PubMed Web of Science ®Google Scholar
• O’ MearaNSturisJVanCouterEPolonskyKLack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitusJ Clin Invest199392262 2718325993
   PubMed Web of Science ®Google Scholar
• MariASallasWMWatsonCVildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetesJ Clin Endocrinol Metab2005904888 489415886245
   PubMed Web of Science ®Google Scholar
• BosiECamisascaRPColloberCEffects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminDiabetes Care200730890 89517277036
   PubMed Web of Science ®Google Scholar
• LukashevichVSchweizerAShaoQSafety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trialDiabetes Obes Metab20111310947 95421733061
   PubMed Web of Science ®Google Scholar
• IwamotoYKashiwagiAYamadaNEfficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled studyDiabetes Obes Metab2010128700 70820590747
   PubMed Web of Science ®Google Scholar
• KikuchiMAbeNKatoMVildagliptin dose dependently improves glycemic control in Japanese patients with type 2 diabetes mellitusDiabetes Res Clin Pract2009832233 24019118913
   PubMed Web of Science ®Google Scholar
• Ahre’nBFoleyJEBosiEClinical evidence and mechanistic basis for vildagliptin’s action when added to metforminDiabetes Obesity Metab2011133193 203
   Web of Science ®Google Scholar
• ZargarABasitAMahtabHSulphonylureas in the management of type 2 diabetes during the fasting month of RamadanJ Indian Med Assoc2005103444 44616363203
   PubMedGoogle Scholar
• ZargarAHSirajMJawaAAHasanMMahtabHMaintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fastInt J Clin Pract2010641090 109420455956
   PubMed Web of Science ®Google Scholar
• Al AroujMAssaad-KhalilSBuseJRecommendations for management of diabetes during Ramadan: updateDiabetes Care2010331895 190220668157
   PubMed Web of Science ®Google Scholar
• MafauzyMRepaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fastingDiabetes Res Clin Pract20025845 5312161056
   PubMed Web of Science ®Google Scholar
• The Glimepiride in Ramadan (GLIRA) Study groupThe efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during RamadanDiabetes Care200528421 42215677804
   PubMed Web of Science ®Google Scholar
• HassaneinMHanifWMalikWComparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR studyCurr Med Res Opin2011271367 137421568833
   PubMed Web of Science ®Google Scholar
• PenfornisABourdel-MarchassonIQuereSDejagerSReal-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type-2 diabetes: the HYPOCRAS studyDiabetes Metab201238550 55722996038
   PubMed Web of Science ®Google Scholar
• DevendraDGohelBBravisVVildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during RamadanInt J Clin Pract2009631446 145019678856
   PubMed Web of Science ®Google Scholar
• FerranniniEFonsecaVZinmanBFifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyDiabetes Obes Metab200911157 16619125777
   PubMed Web of Science ®Google Scholar
• MalhaLPTaanGZantoutMSAzarSMGlycemic effects of vildagliptin in patients with type 2 diabetes before, during and after the period of fasting in RamadanTher Adv Endocrinol Metab2014513 924696775
   PubMedGoogle Scholar
• Anja SchweizerAHalimiSDejagerSExperience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during RamadanVasc Health Risk Manag20141015 2424391442
   PubMedGoogle Scholar
• HalimiSMarc LevyMHuetDQuéréSDejagerSExperience with vildagliptin in type 2 diabetic patients fasting during Ramadan in France: Insights from the VERDI StudyDiabetes Ther20134385 39823996548
   PubMed Web of Science ®Google Scholar
• Al AroujMHassounAAKMedlejRThe effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE studyInt J Clin Pract20136710957 96324001317
   PubMed Web of Science ®Google Scholar
• HassaneinMAbdallahKSchweizerAAdouble-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST studyVasc Health Risk Manag201410319 32624920915
   PubMedGoogle Scholar
• SheteAShaikhANayeemKJVildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during RamadanWorld J Diabetes201346358 36424379927
   PubMedGoogle Scholar
• DejagerSSchweizerAMinimizing the risk of hypoglycemia with vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes managementDiabetes Ther2011251 6622127800
   PubMedGoogle Scholar
• SchweizerADejagerSFoleyJEShaoQKothnyWClinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trialsDiabetes Obes Metab20111355 6421114604
   PubMed Web of Science ®Google Scholar
• DejagerSSchweizerAIncretin therapies in the management of patients with type 2 diabetes mellitus and renal impairmentHosp Pract2012407 21
   PubMedGoogle Scholar
• CharbonnelBSchweizerADejagerSCombination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?Hosp Pract (1995)20134193 10723680741
   PubMedGoogle Scholar
• MatthewsDRDejagerSAhrenBVildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year studyDiabetes Obes Metab201012780 78920649630
   PubMed Web of Science ®Google Scholar
• GaboritBDutourORonsinORamadan fasting with diabetes: an interview study of inpatients’ and general practitioners’ attitudes in the South of FranceDiabetes Metab201137395 40221478041
   PubMed Web of Science ®Google Scholar
• BravisVHuiESalihSMehartSHassaneinMDevendraDRamadan Education and Awareness in Diabetes (READ) programme for Muslims with type 2 diabetes who fast during RamadanDiabet Med201027327 33120536496
   PubMed Web of Science ®Google Scholar
• AhmedaniMYHaqueMSBasitAFawwadAAlviSFRamadan Prospective Diabetes Study: the role of drug dosage and timing alteration, active glucose monitoring and patient educationDiabet Med201229709 71522587405
   PubMed Web of Science ®Google Scholar
• HalimiSLevyMAmgharHClinical case: beliefs, Ramadan and diabetes mellitusAnn Endocrinol (Paris)2004651 SupplS68 S73 French15163926
   PubMed Web of Science ®Google Scholar
• HassaneinMBravisVHuiEDevendraDRamadan-focused education and awareness in type 2 diabetesDiabetologia200952367 36819034417
   PubMed Web of Science ®Google Scholar
• HanifWMalikWHassaneinMTreatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during RamadanCurr Med Res Opin201329807 81123659561
   PubMed Web of Science ®Google Scholar